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with Dead Parasites: Why Predicting Malaria Parasite Clearance Is
Not a Simple Task”
Ian M. Hastings, Katherine Kay, Eva Maria Hodel
Liverpool School of Tropical Medicine, Liverpool, United Kingdom
We welcome the comments of Simpson et al. (1). There isclearly a need to understand the basic properties of parasite
clearance rates and their potential role as policy decision tools.
Simpson et al. state that our models are “limited with respect to
two key parameters, the infecting parasite strain and host immu-
nity.” We address each point in turn, noting that our nomencla-
ture (2) recognized that it is infected red blood cells (iRBC), not
parasites directly, which are cleared from the circulation.
Simpson et al. (1) note that “immunity is complex” (and that
we acknowledged this in our paper) and make the specific point of
immunity reducing the parasite multiplication factor at the end of
the 48-h cycle. We were aware of this factor and addressed it on
page 6432 in the text starting “The dynamics can be understood as
the interactions among the three factors that determine iRBC
clearance dynamics, i.e., spleen clearance rates, sequestration
rates, and new merozoite release rates” (2). We argued that spleen
clearance rates completely dominate any decrease in the rate of
successful RBC invasions of merozoites (equivalent to merozoite
release rates) so took this potential immune effect into account in
our modeling.
Simpson et al. (1) also noted the effect of “infecting parasite
strain.” Importantly, Plasmodium falciparum is sexual, with fre-
quent genetic recombination, so resistant and sensitive “strains”
are defined only by short regions of DNA surrounding the resis-
tance locus. The remainder of the strain genetic background
(which includes antigen-encoding loci) reflects that of the local
population. Interestingly, we did address this issue of immunity
acting against the resistance/sensitivity genotype (or strains) in
our original submission in a paragraph that read as follows (with
citation numbers updated):
There is another, less obvious, way in which iRBC clearance
rates may reflect parasite drug resistance levels. This occurs
if a resistance mutation(s) simultaneously affects both arte-
misinin sensitivity and the iRBC immune profile (i.e., the
extent to which iRBC are recognized by host clearance
mechanisms). Interestingly, this hypothesis occurs fairly
regularly in the literature, most explicitly in the work of
Koella (3), who also cites earlier work by Clyde in 1958 (4)
and by Peters in 1987 (5). Koella discusses three ways in
which this phenomenon may occur: (i) if separate genes
affecting resistance and immune profile are physically
closely linked on the same chromosome, (ii) if a single gene
affects both resistance and immune profile, and/or (iii) if
the mutation alters drug accumulation within the iRBC and
the degree of drug accumulation affects the immune prop-
erties of the iRBC. [We also conjecture that changes in drug
accumulation might affect the physical properties of iRBC,
such as deformability, that might affect splenic clearance
rates]. Koella’s arguments were explicitly applied to chloro-
quine resistance but appear equally applicable to artemis-
inin resistance, although, in both drugs, the first explana-
tion seems less than compelling because current genetic
analyses did not identify immune loci within the resistance
linkage regions. Koella’s second hypothesis seems more
plausible, as changes in the levels of molecules, such as
membrane-bound pumps, may be associated with resis-
tance levels and also affect the iRBC immune profile. Note
also that these immune effects may produce a counterintui-
tive result: if resistance enhances the immune profile, for
example by overproduction of a membrane-bound pump
recognized by immunity, then resistance may actually be-
come associated with higher clearance rates.
This paragraph was removed on the robust advice of an anon-
ymous reviewer. We are delighted to resurrect it because it is
highly pertinent to the current correspondence and to the previ-
ous paper (6), which did not cite this literature. Hastings has long-
standing interest in this area (see, e.g., references 7 and 8), which
made us reluctant to explicitly model “strain” effects, particularly
because relating immunity directly to the resistance genotype
would allow any resistance/clearance relationship to be predicted.
The title of the letter of Simpson et al. (1) states that “predicting
malaria parasite clearance is not a simple task”; we agree entirely,
as this requires details of immunity and parasite biology of which
we remain profoundly ignorant. We argue strongly that even if we
cannot predict them, it is straightforward to interpret them; they
reflect primarily the level of patients’ acquired immunity unless
and until drug effectiveness becomes so low that parasites are not
actually cleared. This makes clearance rates extremely insensitive
and nonspecific metrics of drug effectiveness, which was the key
point that we made in our paper.
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